Single cell RNA-sequencing identified CCR7+/RELB+/IRF1+ T cell responding for juvenile idiopathic arthritis pathogenesis

单细胞RNA测序鉴定出参与幼年特发性关节炎发病机制的CCR7+/RELB+/IRF1+ T细胞

阅读:2

Abstract

BACKGROUND: To further explore the disease heterogeneity of different subtypes of Juvenile idiopathic arthritis (JIA) and analyze their pathogenesis mechanisms. METHOD: The single-cell RNA sequencing (scRNA-seq) analysis of peripheral blood mononuclear cells (PBMCs) was carried out to investigate the disease heterogeneity and molecular mechanisms of immune responses in immune cells in JIA. RESULT: In our study, we provided a immunological landscape of HLA-B27-positive JIA and HLA-B27-negative JIA immune cells at single cell RNA-Seq resolution. We found a higher proportion of CCR7+/RELB+/IRF1+ triple positive T cells in the peripheral blood of patients with JIA, and such T cells were predominantly present in HLA-B27(+) JIA patients. Furthermore, we hypothesized that CCR7+/RELB+/IRF1+ triple positive T cells were highly activated T cells capable of promoting the differentiation of osteoclasts by producing IL-17, thus causing damage to cartilage in HLA-B27(+) JIA patients. Unlike JIA patients, CCR7+/RELB+/IRF1+ triple positive T cells were not found in the peripheral blood of pSS patients and SLE patients, moreover, T cells from pSS patients and SLE patients were less able to produce IL-17 than those from JIA patients. CONCLUSION: Our study provided evidence of cellular and molecular levels of involvement in JIA pathogenesis and identified the critical roles for T cells in JIA pathogenesis. Furthermore, our results suggested that there were significant differences in T cell composition and gene expression between HLA-B27(+) JIA patients and HLA-B27(-) JIA patients. Our findings indicated that CCR7+/RELB+/IRF1+ positive T cells could damage the cartilage of HLA-B27(+) JIA by producing cytokines such as IL-17.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。